Mesenchymal stromal cells as regulators of anti-tumour immune response.

Suppr

超能文献

作者信息

Poggi Alessandro, Zocchi M R

机构信息

Molecular Oncology & Angiogenesis Unit, IRCCS AOU San Martino IST, 16132 Genoa, Italy.

出版信息

Indian J Med Res. 2015 Feb;141(2):139-42. doi: 10.4103/0971-5916.155530.

DOI:10.4103/0971-5916.155530

PMID:25900944

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4418145/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea5/4418145/e64b235e7836/IJMR-141-139-g001.jpg

相似文献

Mesenchymal stromal cells as regulators of anti-tumour immune response.

Indian J Med Res. 2015 Feb;141(2):139-42. doi: 10.4103/0971-5916.155530.

Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme.

J Exp Med. 2020 Apr 6;217(4). doi: 10.1084/jem.20190457.

Mesenchymal stromal cells: a key player in 'innate tolerance'?

Immunology. 2012 Nov;137(3):206-13. doi: 10.1111/j.1365-2567.2012.03621.x.

Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.

Br J Cancer. 2015 Mar 17;112(6):1067-75. doi: 10.1038/bjc.2015.29.

Allogeneic mesenchymal stem cells: agents of immune modulation.

J Cell Biochem. 2011 Aug;112(8):1963-8. doi: 10.1002/jcb.23119.

[Stromal cells as coordinators of adaptive immune response and immunological memory].

Z Rheumatol. 2013 Dec;72(10):986-92. doi: 10.1007/s00393-012-1031-7.

Mesenchymal Stem Cells, Immune Cells and Tumor Cells Crosstalk: A Sinister Triangle in the Tumor Microenvironment.

Curr Stem Cell Res Ther. 2019;14(1):43-51. doi: 10.2174/1574888X13666180816114809.

Immunotherapy in the context of hematopoietic stem cell transplantation: the emerging role of natural killer cells and mesenchymal stromal cells.

Pediatr Clin North Am. 2010 Feb;57(1):97-121. doi: 10.1016/j.pcl.2009.12.001.

Immune properties of mesenchymal stem cells.

Methods Mol Biol. 2007;407:225-43. doi: 10.1007/978-1-59745-536-7_16.

Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):e26-e43. doi: 10.1097/PAI.0000000000000629.

本文引用的文献

Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Front Immunol. 2014 Dec 4;5:619. doi: 10.3389/fimmu.2014.00619. eCollection 2014.

Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Nat Rev Immunol. 2015 Jan;15(1):45-56. doi: 10.1038/nri3790.

Rural urban differences in breast cancer in India.

Indian J Cancer. 2014 July-September;51(3):277-281. doi: 10.4103/0019-509X.146793.

CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.

Indian J Med Res. 2014 Sep;140(3):361-9.

Indian Council of Medical Research consensus document for the management of colorectal cancer.

Indian J Med Paediatr Oncol. 2014 Jul;35(3):192-6. doi: 10.4103/0971-5851.142031.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16.

TGFβ in T cell biology and tumor immunity: Angel or devil?

Cytokine Growth Factor Rev. 2014 Aug;25(4):423-35. doi: 10.1016/j.cytogfr.2014.07.014. Epub 2014 Jul 29.

Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells.

Transl Res. 2015 Jan;165(1):126-42. doi: 10.1016/j.trsl.2014.04.001. Epub 2014 Apr 12.

Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.

Immunol Lett. 2014 May-Jun;159(1-2):55-72. doi: 10.1016/j.imlet.2014.03.001. Epub 2014 Mar 20.

How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases.

Oncoimmunology. 2013 Dec 1;2(12):e27089. doi: 10.4161/onci.27089. Epub 2013 Dec 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验